VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 365 filers reported holding VALEANT PHARMACEUTICALS INTL in Q3 2016. The put-call ratio across all filers is 0.92 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2016 | $201,000 | -99.4% | 10,000 | -97.2% | 0.01% | -99.5% |
| Q4 2015 | $35,558,000 | -57.6% | 351,402 | -25.6% | 2.29% | -56.8% |
| Q3 2015 | $83,878,000 | -28.1% | 472,102 | -10.2% | 5.31% | -20.6% |
| Q2 2015 | $116,724,000 | -1.4% | 525,946 | -12.2% | 6.69% | +14.4% |
| Q1 2015 | $118,342,000 | +4.3% | 599,017 | -24.2% | 5.84% | +14.4% |
| Q4 2014 | $113,421,000 | +22.3% | 789,812 | +11.9% | 5.11% | +15.8% |
| Q3 2014 | $92,722,000 | -12.1% | 706,112 | -15.2% | 4.41% | +3.5% |
| Q2 2014 | $105,535,000 | +9.2% | 833,041 | +25.3% | 4.26% | -7.1% |
| Q1 2014 | $96,657,000 | +12.5% | 664,581 | -3.6% | 4.59% | +12.8% |
| Q4 2013 | $85,892,000 | +20.6% | 689,231 | +4.0% | 4.07% | +7.6% |
| Q3 2013 | $71,210,000 | +14.4% | 663,031 | -3.4% | 3.78% | +3.6% |
| Q2 2013 | $62,251,000 | – | 686,491 | – | 3.65% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chou Associates Management | 1,648,992 | $38,323,000 | 14.52% |
| Paulson & Co. | 20,839,035 | $484,299,000 | 9.89% |
| MILLER VALUE PARTNERS, LLC | 4,999,064 | $116,178,000 | 4.34% |
| GoldenTree Asset Management | 1,140,205 | $26,498,000 | 4.21% |
| Pomelo Capital LLC | 1,760,000 | $40,902,000 | 4.00% |
| Bruce & Co., Inc. | 860,000 | $19,986,000 | 3.98% |
| ValueAct Holdings | 18,033,149 | $419,090,000 | 3.79% |
| Stanley Capital Management, LLC | 318,400 | $7,400,000 | 3.25% |
| Kazazian Asset Management, LLC | 134,784 | $3,132,000 | 2.87% |
| Phoenix Investment Adviser LLC | 58,400 | $1,357,000 | 2.48% |